- Home
- ADAMZ vs AVDL Comparison
ADAMZ vs AVDL Comparison
Compare ADAMZ & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAMZ
- AVDL
- Stock Information
- Founded
- ADAMZ N/A
- AVDL 2015
- Country
- ADAMZ United States
- AVDL Ireland
- Employees
- ADAMZ N/A
- AVDL N/A
- Industry
- ADAMZ Real Estate Investment Trusts
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- ADAMZ Real Estate
- AVDL Health Care
- Exchange
- ADAMZ Nasdaq
- AVDL Nasdaq
- Market Cap
- ADAMZ 1.6B
- AVDL 1.5B
- IPO Year
- ADAMZ N/A
- AVDL 1996
- Fundamental
- Price
- ADAMZ $19.40
- AVDL $18.57
- Analyst Decision
- ADAMZ
- AVDL Buy
- Analyst Count
- ADAMZ 0
- AVDL 10
- Target Price
- ADAMZ N/A
- AVDL $18.94
- AVG Volume (30 Days)
- ADAMZ N/A
- AVDL 4.3M
- Earning Date
- ADAMZ N/A
- AVDL 11-11-2025
- Dividend Yield
- ADAMZ N/A
- AVDL N/A
- EPS Growth
- ADAMZ N/A
- AVDL N/A
- EPS
- ADAMZ N/A
- AVDL N/A
- Revenue
- ADAMZ N/A
- AVDL $221,075,000.00
- Revenue This Year
- ADAMZ N/A
- AVDL $64.21
- Revenue Next Year
- ADAMZ N/A
- AVDL $30.80
- P/E Ratio
- ADAMZ N/A
- AVDL N/A
- Revenue Growth
- ADAMZ N/A
- AVDL 132.35
- 52 Week Low
- ADAMZ N/A
- AVDL $6.38
- 52 Week High
- ADAMZ N/A
- AVDL $18.65
- Technical
- Relative Strength Index (RSI)
- ADAMZ N/A
- AVDL 79.97
- Support Level
- ADAMZ N/A
- AVDL $13.83
- Resistance Level
- ADAMZ N/A
- AVDL $18.65
- Average True Range (ATR)
- ADAMZ 0.00
- AVDL 0.59
- MACD
- ADAMZ 0.00
- AVDL 0.43
- Stochastic Oscillator
- ADAMZ 0.00
- AVDL 97.93
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.